The ADALA trial evaluated 3-month post-procedural strategies after left atrial appendage occlusion (LAAO) using low-dose apixaban versus dual antiplatelet therapy (DAPT).
Low-dose apixaban significantly reduced the composite primary endpoint of major bleeding and thromboembolic events compared to DAPT (4.5% vs 21.7%).
Device-related thrombosis (DRT) was absent in the low-dose apixaban group versus 8.7% incidence with DAPT.
No strokes or systemic embolism events were observed in either group during follow-up.
